CITIUS ONCOLOGY, INC. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Symbol
CTOR on Nasdaq
Location
Cranford, NJ
Fiscal year end
30 September
Latest financial report
13 Feb 2026

Latest SEC snapshot (2025-12-31) highlights Return On Equity -47.4%, Return On Assets -23.6%, and Operating Margin -133.2%.

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

28.4/100

Weak Confidence medium

Return On Equity

-47%

Metric score 0.0/100

Return On Assets

-24%

Metric score 0.0/100

Financial Health

Current Ratio
0.83x
Quick Ratio
0.32x
Debt to Equity
1.3x

Strengths

Current Ratio

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Return On Equity

-47%

YoY: -34%

Industry median: -43% (n=671)

View history

Return On Assets

-24%

YoY: -17%

Industry median: -48% (n=669)

View history

Operating Margin

-133%

YoY:

Industry median: -128% (n=298)

View history

Current Ratio

0.83x

YoY: +111%

Industry median: 3.39x (n=667)

View history

Quick Ratio

0.32x

YoY: +422%

Industry median: 2.02x (n=287)

View history

Debt-to-equity

1.3x

YoY:

Industry median: 0.28x (n=634)

View history

NetIncomeLoss YoY

-2.4%

YoY:

Industry median: -0.54% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity -47% -34%
Return On Assets -24% -17%
Operating Margin -133%

Financial Health

Metric Latest value YoY change
Current Ratio 0.83x +111%
Quick Ratio 0.32x +422%
Debt-to-equity 1.3x

Growth

Metric Latest value YoY change
Revenues $3,944,111
NetIncomeLoss YoY -2.4%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 84,797,846 +19%
Common Stock, Shares, Outstanding 84,797,846 +19%
Common Stock, Value, Issued $8,480 +19%
Weighted Average Number of Shares Outstanding, Basic 87,462,385 +22%
Weighted Average Number of Shares Outstanding, Diluted 87,462,385 +22%

Additional Metrics

Metric Latest value YoY change
Cost of Revenue $789,208
Research and Development Expense $6,172,178 +22%
General and Administrative Expense $8,321,357 -16%
Operating Income (Loss) $5,252,276 +18%
Nonoperating Income (Expense) $17,553
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $22,579,273 -0.87%
Income Tax Expense (Benefit) $1,056,960 +52%
Earnings Per Share, Basic -0.31 +6.1%
Earnings Per Share, Diluted -0.31 +6.1%
Accounts Receivable, after Allowance for Credit Loss, Current $4,049,111
Inventory, Net $22,639,342 +57%
Assets, Current $37,146,844 +117%
Assets $109,973,406 +22%
Accounts Payable, Current $10,446,900 +78%
Accrued Liabilities, Current $4,518,916 -27%
Liabilities, Current $44,710,394 +3%
Deferred Income Tax Liabilities, Net $3,049,200 +53%
Liabilities $51,559,705 +4.8%
Retained Earnings (Accumulated Deficit) $69,574,025 -51%
Stockholders' Equity Attributable to Parent $58,413,701 +41%
Liabilities and Equity $109,973,406 +22%
Share-based Payment Arrangement, Noncash Expense $3,956,050 +119%
Increase (Decrease) in Accounts Receivable $4,049,111
Net Cash Provided by (Used in) Operating Activities $7,354,946
Net Cash Provided by (Used in) Financing Activities $15,125,489
Net Cash Provided by (Used in) Investing Activities $4,400,000
Common Stock, Shares Authorized 400,000,000 +300%
Common Stock, Shares, Issued 84,797,846 +19%
Common Stock, Par or Stated Value Per Share 0.0001 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities $14,460
Deferred Income Tax Expense (Benefit) $264,240 0%
Preferred Stock, Shares Authorized 10,000,000 0%
Additional Paid in Capital $127,979,246 +47%
Preferred Stock, Par or Stated Value Per Share 0.0001 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%